Having trouble accessing articles? Reset your cache.

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

NIBR identifies CPSF3 as novel synthetic lethality target in subsets of AML, sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas.

The premise of synthetic lethality is that genomic or pharmacologically induced defects that are tolerated individually become lethal when combined. The prime example is PARP inhibition,

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers